PharmaCyte Biotech PMCB
NASDAQ PMCB
$0.35 +0.01 (+1.86%)
As of: Oct 22, 2026 · 3:59 PM EDT

PharmaCyte Biotech (PMCB) Change in Receivables (2010 - 2012)

Updated

PharmaCyte Biotech's Change in Receivables was -$2,581 in FY2013 (year ended Apr 30, 2013), compared with $6,762 in FY2012.

Analysis

PharmaCyte Biotech (PMCB) Change in Receivables (2010 - 2012) Analysis & Trends

  • Per Business Quant data, Change in Receivables in earlier fiscal years was $6,762 in FY2012 and -$931.00 in FY2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -188.00 Mn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 1.37 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 1.09 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 333.00 Mn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 PharmaCyte Biotech 3.79 Mn -69.05 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jul 31, 2012 -2,581.00
Apr 30, 2012 -10,501.00
Jan 31, 2012 10,617.00
Oct 31, 2011 12,937.00
Jul 31, 2011 -6,291.00
Apr 30, 2011 18,976.00
Jan 31, 2011 -17,317.00
Oct 31, 2010 -8,677.00
Jul 31, 2010 6,087.00
API Access

PharmaCyte Biotech Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=PMCB&period=max&api_key=YOUR_API_KEY